Literature DB >> 1536178

Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review.

B A Valentine1, N J Winand, D Pradhan, N S Moise, A de Lahunta, J N Kornegay, B J Cooper.   

Abstract

Canine X-linked muscular dystrophy is a spontaneously occurring, progressive, degenerative myopathy of dogs that is clinically and pathologically similar to Duchenne muscular dystrophy in man. The molecular basis for the disease has been shown to be a lack of dystrophin, the protein product of the Duchenne muscular dystrophy gene. Breeding colonies of dystrophic dogs have been established. This report reviews the findings of genetic, clinical, pathologic, molecular biologic, and immunocytochemical studies of the canine model, and compares the features of the canine disease to those of Duchenne dystrophy in man.

Entities:  

Mesh:

Year:  1992        PMID: 1536178     DOI: 10.1002/ajmg.1320420320

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  34 in total

Review 1.  Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse.

Authors:  J M Gillis
Journal:  J Muscle Res Cell Motil       Date:  1999-10       Impact factor: 2.698

2.  Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy.

Authors:  Yuko Nitahara-Kasahara; Hiromi Hayashita-Kinoh; Sachiko Ohshima-Hosoyama; Hironori Okada; Michiko Wada-Maeda; Akinori Nakamura; Takashi Okada; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

Review 3.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 4.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

Review 5.  Approaching a new age in Duchenne muscular dystrophy treatment.

Authors:  Kathryn R Wagner
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

6.  Inhibition of antigen presentation during AAV gene therapy using virus peptides.

Authors:  Wenwei Shao; Xiaojing Chen; Richard J Samulski; Matthew L Hirsch; Chengwen Li
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

Review 7.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

Review 8.  Animal models for genetic neuromuscular diseases.

Authors:  Mariz Vainzof; Danielle Ayub-Guerrieri; Paula C G Onofre; Poliana C M Martins; Vanessa F Lopes; Dinorah Zilberztajn; Lucas S Maia; Karen Sell; Lydia U Yamamoto
Journal:  J Mol Neurosci       Date:  2008-01-18       Impact factor: 3.444

9.  Respiratory dysfunction in unsedated dogs with golden retriever muscular dystrophy.

Authors:  Justin C DeVanna; Joe N Kornegay; Daniel J Bogan; Janet R Bogan; Jennifer L Dow; Eleanor C Hawkins
Journal:  Neuromuscul Disord       Date:  2013-10-24       Impact factor: 4.296

10.  Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: implications for a new canine leukemia model.

Authors:  Monica S Thakar; Xiao-Bing Zhang; Brian C Beard; George E Sale; Erlinda B Santos; Laura Peterson; Hans-Peter Kiem; Brenda M Sandmaier
Journal:  Exp Hematol       Date:  2009-07-17       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.